Obsidian

Obsidian Therapeutics Announces Clinical & Preclinical Presentations at the American Association of Cancer Research Annual Meeting

Retrieved on: 
Tuesday, March 5, 2024

Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced presentations reporting initial clinical data from the ongoing first-in-human study of OBX-115 and preclinical data from our cytoDRiVE® platform demonstrating regulatable cytoTIL15 signal transduction in cis and trans, as well as the ability of a single drug-responsive domain (DRD) to coregulate two cytokines, LIGHT and mbIL15, in tumor-infiltrating lymphocytes (TIL) during the American Association of Cancer Research (AACR) Annual Meeting, which will be held April 5-10, 2024 in San Diego, CA.

Key Points: 
  • Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced presentations reporting initial clinical data from the ongoing first-in-human study of OBX-115 and preclinical data from our cytoDRiVE® platform demonstrating regulatable cytoTIL15 signal transduction in cis and trans, as well as the ability of a single drug-responsive domain (DRD) to coregulate two cytokines, LIGHT and mbIL15, in tumor-infiltrating lymphocytes (TIL) during the American Association of Cancer Research (AACR) Annual Meeting, which will be held April 5-10, 2024 in San Diego, CA.
  • These data follow the announcement of positive top-line results from the ongoing first-in-human, Phase 1 clinical trial evaluating the safety and efficacy of OBX-115, Obsidian’s lead engineered TIL cell therapy candidate, in patients with metastatic melanoma that has relapsed and/or is refractory to prior immune checkpoint inhibitor (ICI) therapy ( NCT05470283 ).
  • The details of these posters are as follows:
    Presenting Author: Rodabe N Amaria, The University of Texas MD Anderson Cancer Center, Houston, TX

enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary

Retrieved on: 
Tuesday, January 30, 2024

Experienced biotech executive brings public company expertise in legal, corporate governance, and compliance to support enGene during late-stage clinical development and anticipated future commercial launch of its lead program EG-70

Key Points: 
  • Experienced biotech executive brings public company expertise in legal, corporate governance, and compliance to support enGene during late-stage clinical development and anticipated future commercial launch of its lead program EG-70
    BOSTON and MONTREAL, Jan. 30, 2024 /PRNewswire/ - enGene Holdings Inc. ("enGene," (Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment of Lee Giguere as Chief Legal Officer and Corporate Secretary.
  • "I am delighted to welcome Lee, an experienced public biotech legal executive, to enGene as we advance the development of EG-70 in our ongoing pivotal-stage LEGEND study in BCG-unresponsive non-muscle invasive bladder cancer," said Jason D. Hanson, Chief Executive Officer of enGene.
  • Mr. Giguere previously served as Chief Legal Officer and Secretary of Obsidian Therapeutics, a clinical-stage cell and gene therapy company.
  • Mr. Giguere commented: "I am thrilled to join enGene as we work to transform the management of bladder cancer, beginning with BCG-unresponsive NMIBC.

The Obsidian Co.: A Digital Marketing Startup Takes on Industry Leaders in the Drum Awards 2023

Retrieved on: 
Tuesday, January 9, 2024

This accomplishment solidifies its position as a formidable competitor to established digital advertising giants.

Key Points: 
  • This accomplishment solidifies its position as a formidable competitor to established digital advertising giants.
  • To view an enhanced version of this graphic, please visit:
    Despite its roots as a startup, The Obsidian Co. fearlessly confronts industry leaders.
  • Christos I. Loizou, CEO and Founder, affirms, "Challenging norms and pushing the boundaries of digital advertising has been our founding principle.
  • The winners of The Drum Awards' "Agency Team of the Year" were unveiled during a live ceremony in London on the 6th of December, 2023.

Kandao Unveils Qoocam 3 Ultra at CES 2024

Retrieved on: 
Thursday, December 21, 2023

The highlight of Kandao's presence at CES 2024 will be the unveiling of the QooCam 3 Ultra, a cutting-edge consumer-level 360 camera that hits stores in 2024.

Key Points: 
  • The highlight of Kandao's presence at CES 2024 will be the unveiling of the QooCam 3 Ultra, a cutting-edge consumer-level 360 camera that hits stores in 2024.
  • In addition to the highly anticipated QooCam 3 Ultra, Kandao will showcase other exceptional products that have garnered industry recognition and acclaim.
  • "We are proud to showcase our lineup of innovative products at CES 2024, including the highly anticipated QooCam 3 Ultra," said Dan Chen, CEO at Kandao.
  • Kandao invites all attendees of CES 2024 to visit booth 16854 in the central hall to explore its comprehensive range of VR cameras.

Kandao Unveils Qoocam 3 Ultra at CES 2024

Retrieved on: 
Thursday, December 21, 2023

The highlight of Kandao's presence at CES 2024 will be the unveiling of the QooCam 3 Ultra, a cutting-edge consumer-level 360 camera that hits stores in 2024.

Key Points: 
  • The highlight of Kandao's presence at CES 2024 will be the unveiling of the QooCam 3 Ultra, a cutting-edge consumer-level 360 camera that hits stores in 2024.
  • In addition to the highly anticipated QooCam 3 Ultra, Kandao will showcase other exceptional products that have garnered industry recognition and acclaim.
  • "We are proud to showcase our lineup of innovative products at CES 2024, including the highly anticipated QooCam 3 Ultra," said Dan Chen, CEO at Kandao.
  • Kandao invites all attendees of CES 2024 to visit booth 16854 in the central hall to explore its comprehensive range of VR cameras.

Obsidian Therapeutics Announces Positive Interim Top-Line Clinical Data for OBX-115 Engineered TIL Cell Therapy in Advanced or Metastatic Melanoma Post-Anti-PD1 Therapy

Retrieved on: 
Tuesday, December 12, 2023

OBX-115 is an investigational novel IL2-sparing engineered TIL cell therapy armed with pharmacologically regulatable membrane-bound IL15 designed to enhance persistence, anti-tumor activity, and clinical safety of TIL cell therapy relative to unengineered TIL therapy plus high-dose IL2.

Key Points: 
  • OBX-115 is an investigational novel IL2-sparing engineered TIL cell therapy armed with pharmacologically regulatable membrane-bound IL15 designed to enhance persistence, anti-tumor activity, and clinical safety of TIL cell therapy relative to unengineered TIL therapy plus high-dose IL2.
  • , professor of Melanoma Medical Oncology and principal investigator of the study at The University of Texas MD Anderson Cancer Center.
  • “The OBX-115 data show its potential to be a meaningful advancement in the treatment of metastatic melanoma and TIL cell therapy,” said Parameswaran Hari, M.D., M.S., Chief Development Officer of Obsidian Therapeutics.
  • “These positive results underscore the potential for OBX-115 TIL cell therapy to offer patients with metastatic melanoma a differentiated TIL therapy without the need for IL2,” said Madan Jagasia, M.D., M.S., CEO of Obsidian Therapeutics.

Obsidian Security Recognized as Strong Performer by Independent Research Firm

Retrieved on: 
Monday, December 11, 2023

Additionally, the Obsidian Integration Risk Management module received the highest possible score in the connected apps criterion.

Key Points: 
  • Additionally, the Obsidian Integration Risk Management module received the highest possible score in the connected apps criterion.
  • Forrester also gave Obsidian the highest score possible in the IAM administration criterion supported by Obsidian Advanced Threat Mitigation module.
  • The Forrester report recognized Obsidian as a vendor providing “a single, modular platform” for SaaS Security and Posture Management.
  • With a focus on tangible capabilities and robust security measures, Obsidian remains a trusted partner for organizations seeking top-tier SSPM solutions.

KLEVV INTRODUCES CRAS V RGB KIT WITH DDR5-8400 WITH ALL-NEW BRILLIANT WHITE EDITION

Retrieved on: 
Monday, December 18, 2023

HONG KONG, Dec. 17, 2023 /PRNewswire/ -- KLEVV, the premier consumer memory and storage brand introduced by Essencore, today is excited to unveil the all-new CRAS V RGB Brilliant White edition memory kit available in extreme high speed of 8200MT/s & 8400MT/s configurations.

Key Points: 
  • HONG KONG, Dec. 17, 2023 /PRNewswire/ -- KLEVV, the premier consumer memory and storage brand introduced by Essencore, today is excited to unveil the all-new CRAS V RGB Brilliant White edition memory kit available in extreme high speed of 8200MT/s & 8400MT/s configurations.
  • As a testament to the immense popularity and growing demand for the CRAS V RGB memory kits, KLEVV has responded by introducing the long-awaited Brilliant White edition to its flagship memory lineup as well as two high-speed options for consumers.
  • These specifications are accessible in the Obsidian Black edition and the newly unveiled Brilliant White edition memory kits, both available in a 24GBx2 configuration.
  • The CRAS V RGB Brilliant White edition memory kits and high-speed modules will be available from the end of December 2023,  KLEVV products are distributed by Integral Memory plc in the United Kingdom/ France/ Spain/ Germany.

enGene Appoints Ryan Daws as Chief Financial Officer

Retrieved on: 
Wednesday, November 29, 2023

BOSTON and MONTREAL, Nov. 29, 2023 /PRNewswire/ - enGene Holdings Inc. ("enGene,") (NASDAQ: ENGN) (NASDAQ: ENGNW), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment of Ryan Daws as Chief Financial Officer and Head of Business Development.

Key Points: 
  • BOSTON and MONTREAL, Nov. 29, 2023 /PRNewswire/ - enGene Holdings Inc. ("enGene,") (NASDAQ: ENGN) (NASDAQ: ENGNW), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment of Ryan Daws as Chief Financial Officer and Head of Business Development.
  • "I am delighted to welcome Ryan to enGene at a critical time in our growth, as we move forward as a public company and work to advance our ongoing pivotal-stage EG-70 clinical study in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)," said Jason D. Hanson, Chief Executive Officer of enGene.
  • Prior to joining enGene, Mr. Daws was Chief Financial Officer and Head of Business Development at Obsidian Therapeutics, Inc.
  • Mr. Daws also previously served as Chief Financial Officer and Head of Business Development at Concert Pharmaceuticals, Inc.

All-New 2024 Hyundai Santa Fe Revealed at AutoMobility LA with Wider 'Open for More' Liftgate Opening

Retrieved on: 
Thursday, November 16, 2023

The 2024 Santa Fe 2.5T model goes on sale in March 2024, with the Hybrid model on sale in spring.

Key Points: 
  • The 2024 Santa Fe 2.5T model goes on sale in March 2024, with the Hybrid model on sale in spring.
  • Santa Fe enhances its city-friendly, adventure-ready appeal with a generous, terrace-like living space created by its new, longer wheelbase and larger liftgate opening.
  • With the 2024 Santa Fe, we continue our impressive transformation of the Hyundai brand and the broader SUV landscape.
  • The new, wide liftgate design is nearly six inches wider than the previous generation Santa Fe.